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Abstract
Current evidence suggests that although persistent arthritic pain is
initiated and maintained by articular pathology, it is also heavily
influenced by a range of other factors. Strategies for treating
arthritic pain are therefore different from those adopted for acute
pain. Although published guidelines offer general assistance, the
complexity of underlying mechanisms requires that measures
designed to relieve pain must take into account individual
biological, psychological and societal factors. It follows that a
combination of both pharmacological and non-pharmacological
approaches offers the best opportunity for therapeutic success,
although determining the effectiveness of such complex
interventions remains difficult. Pharmacological therapy is often
prolonged, and safety and tolerability issues become as important
as efficacy over time.
Introduction
Arthritic pain is common and is associated with worse
functional outcomes and poorer quality of life when
compared with a range of other chronic conditions [1]. A
bewildering array of guidelines and other evidence-based
resources are available, but the variability of therapeutic
responses can lead to frustration and disappointment for
both patients and health professionals.
This review categorizes different pain states associated with
arthritis and discusses the extent to which an understanding
of underlying mechanisms can be used to inform the choice
of analgesic therapy. Although a detailed and systematic
evaluation of specific interventions is beyond the scope of the
review, evidence for the utility of general approaches is
presented. The limitations of current approaches to assess-
ment and management are discussed along with the rationale
for use of integrated care in patients with persistent pain.
Mechanisms of pain
Pain classification
Traditionally, pain has been regarded as being either noci-
ceptive (arising in response to tissue injury) or neuropathic
(arising in response to nerve injury). Although this distinction
has had some therapeutic utility, it has served to maintain the
Cartesian concept of a fixed immutable pain system that
faithfully transmits information from a site of injury to pain
centres within the brain. Although this is largely true after
acute injury, it is clear from epidemiological studies that in the
presence of persistent disease a range of additional factors,
often unrelated to the musculoskeletal system, serve to
modify activity within pain (nociceptive) pathways.
Implicit in recent classification schemes is the notion that
acute and chronic pain states are different and that functional
changes within the nociceptive system are important in
determining the signs and symptoms experienced by
individuals with somatic disease [2]. Currently, four different
pain states are recognized (Figure 1). The first of these,
nociceptive pain, refers to those transient symptoms and
signs that arise in response to acute injury and reflects the
activation of specialized pain receptors (nociceptors) and
corresponding activity in more central pathways. Under these
conditions, symptoms broadly reflect the initiating stimulus or
injury; treatment at a peripheral level is likely to be successful.
In contrast, neuroplastic pain (also called inflammatory pain)
occurs in response to more persistent tissue injury and is the
most common pain state associated with musculoskeletal
disease [3]. It arises as a result of mediators released from
damaged tissues acting to increase the excitability of the
nociceptive pathway and has the effect of making everyday
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activities such as standing or walking painful. Effective
therapy requires that attention be directed to both the
originating injury and those additional factors (see below) that
influence nociceptive activity.
Third, neuropathic pain occurs in the presence of nerve injury,
as might occur in association with carpal tunnel syndrome or
after lumbar disc prolapse. Ectopic expression of ion
channels, receptors and related phenomena occur in both
injured and neighbouring non-injured neurons, with resultant
regional pain hypersensitivity and sensory disturbance.
There is currently debate as to the origins of a fourth pain
category, idiopathic pain, which covers such medically
unexplained disorders as fibromyalgia syndrome, irritable
bowel syndrome and tension headache. In all of these
disorders, evidence for peripheral pathology is minimal and
symptoms are considered to reflect disordered pain
processing at more central levels.
Arthritic pain
At a local level, mediators released from synovium, bone or
other tissues will induce the sensitization of articular pain
receptors. The clinical correlate of sensitization at this
peripheral level is that musculoskeletal symptoms will be
localized, with a relatively close relationship to mechanical
stimuli such as walking or standing (Figure 2). Treatment with
systemic or topical therapies designed to reduce inflam-
matory mediators might be expected to have a beneficial
effect, which is in accord with clinical experience [4].
In chronic conditions such as osteoarthritis (OA) or
rheumatoid arthritis (RA), neural sensitization will not be
confined to the periphery. The finding of increased areas of
punctate hyperalgesia in patients with RA after topical
application of capsaicin is in accord with increased
excitability of spinal neurons in this condition [5]. Clinically,
this leads to enhanced pain perception at the site of injury, as
well as to the development of pain and tenderness in normal
tissues both adjacent to and removed from the primary site.
Spinal nociceptive processing in arthritic patients is under the
influence of descending inhibitory controls and inputs from other
somatic structures [6]. Both previous pain episodes and genetic
factors are also likely to influence activity. The multiplicity of
mediators involved provides an opportunity for therapeutic
intervention, and many of the commonly used therapeutic
strategies including acupuncture, transcutaneous electrical
nerve stimulation (TENS) and pharmacological agents such as
non-steroidal anti-inflammatory drugs (NSAIDs) and the weaker
opioid drugs are likely to be exerting an effect at this level.
Psychological and social factors have been shown to be the
most important predictors of both the presence and severity
Figure 1
Classification of pain. Nociceptive pain is triggered by tissue injury and
activates unmodified nociceptive neurons (light arrow) inducing acute
pain. In contrast, normally innocuous stimuli produce pain in
neuropathic and neuroplastic conditions in consequence of sensitized
nociceptive pathways (dark arrows). Note: Idiopathic pain omitted from
figure. (Adapted from [3].)
Figure 2
Causes and consequences of neural plasticity. Although tissue injury
or inflammation can trigger nociceptor sensitization in peripheral
neurons (1), other somatic, psychological and environmental influences
are likely to determine the magnitude of any subsequent change as a
result of modulation of activity at spinal (2) or cortical (3) levels.
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(page number not for citation purposes)
of pain in a range of disorders including RA, OA and
persistent low back pain. It seems logical to assume, but
remains unproven, that these external factors modulate noci-
ceptive processing at a supraspinal or cortical level [7]. The
overall effect is to enhance pain perception and to increase
pain reporting and behavioural change, including disability.
Reliance on peripherally or spinally active therapies alone is
unlikely to prove successful in those patients with more
general symptoms arising from central sensitization.
Prostanoid and opioid receptors are constitutively expressed
in cortical tissues, and the relevant therapeutic agents are
undoubtedly exerting an effect at this level. Nevertheless,
additional measures often using non-pharmaceutical
approaches, including education and cognitive behavioural
therapy, may be required.
Despite the progress that has been made over the past
several decades to define key pain processes, the need
remains to translate this knowledge into better assessment
techniques and more effective pain therapy. Attempts to
devise mechanism-based approaches to therapy have met
with mixed success, in part as a result of lack of clinical
techniques by which to define specific nociceptive
processes. Quantitative sensory tests and cortical imaging
can be used to quantify central changes associated with
articular pathology but are not suitable for more general
clinical use. In practical terms, the duration of symptoms is
important: the likelihood of a significant central component
increases with time. Referred pain and tenderness away from
the site of joint pathology are suggestive of a neuroplastic
pain state, whereas radicular pain is inevitably associated
with neuropathic syndromes.
General approaches to pain management
Clinical guidelines
Published goals for the management of both OA and RA
include the prevention or amelioration of joint damage, the
prevention of loss of function, and the reduction of pain [8,9].
In the absence of complete remission, it is suggested that
longitudinal plans for pain management take into account
adverse effects and costs, as well as the patient’s risk
factors, co-morbid conditions and preferences [9].
Guidelines are increasingly used in a range of settings to
promote effective multidisciplinary health care (Figure 3).
Although clinical guidelines for the management of arthritic
pain have been published, their development has been
hampered by often insufficient, or frankly contradictory, evidence
[8,9]. As outlined in the previous section, persistent joint pain
arises in response to a range of different factors, and it has
proved difficult to adapt evidence obtained from often tightly
controlled research trials to more general clinical settings.
A further problem has been the paucity of techniques by
which the effects of analgesic intervention can be monitored.
In practice, although the assessment and integration of
available information by an individual health professional
might be of high quality, it often proves difficult to
systematically quantify the effects of any subsequent
intervention. Pain is a subjective experience, and although pain
intensity can be monitored with visual analogue scales, other
aspects of the pain experience have proved more difficult to
capture. Instruments such as the McGill pain questionnaire
purport to measure these other domains but have been used
mostly for research purposes.
Education and behavioural change
Patient education has been recommended as a fundamental
component of arthritic pain management; however, objective
evidence for efficacy remains poor. Systematic reviews report
few well-designed randomized controlled trials (RCTs) of
education alone [10]. In contrast, more substantial evidence
exists for the efficacy of lifestyle modification, particularly
exercise and weight reduction [11].
Several systematic reviews evaluating aerobic and strength-
ening exercises have demonstrated clear benefits with regard
Available online http://arthritis-research.com/content/9/3/214
Figure 3
Principles for the management of osteoarthritis: a suggested
sequential pyramidal approach to symptom management. (Adapted
from [49].)to both pain reduction and improved function in people with
knee and hip OA [12]. Weight loss also reduces OA-
associated knee pain in overweight individuals and improves
physical activity, especially when combined with regular
exercise [13]. Measures that maintain adherence to a regime,
such as keeping a personal diary or social support from
friends, are thought to improve long-term outcome [11].
Braces and orthotics can also be effective, although evidence
for the efficacy of these measures has yet to be fully
established in clinical trials.
A small proportion of patients with identifiable musculoskeletal
pathology experience extreme and widespread symptoms,
often associated with recognizable behavioural changes
indicative of a chronic pain syndrome. These individuals may
benefit from psychological/cognitive-behavioural therapies as
part of a multidisciplinary strategy. Accumulating evidence
attests to the efficacy of these approaches in such patients
and is reviewed elsewhere [14].
Pharmacological therapies
Paracetamol (acetaminophen)
This drug has been used for over 100 years; however, its
mechanism of action remains uncertain [15]. Currently, it has
no known endogenous binding sites, but various claims have
been made about inhibition of central cyclooxygenase activity,
inhibition of N-methyl-D-aspartate receptor activity, and
stimulation of descending inhibitory pathways [16].
Paracetamol is effective in many arthritic conditions and
across all age groups. It has been recommended as the oral
analgesic of choice for mild to moderate pain in OA [17] and
is generally well tolerated in osteoarthritic patients for periods
of up to 12 months [18]. In general, paracetamol has a good
tolerability profile and overall safety record, although recently
the frequency of use has been reported to be independently
associated with a moderate increase in the risk of incident
hypertension [19].
Tramadol
Tramadol is a central-acting oral analgesic that has a unique
dual mechanism of action involving both a weak µ-agonist
action as well as inhibition of the reuptake of noradrenaline
(norepinephrine) and serotonin. It has received widespread
approval for use in both moderate and severe pain and has
found use as adjunctive therapy for arthritic pain [20].
Tramadol combines favourably with paracetamol and permits
a decrease in the use of NSAIDs without compromising
analgesia [21]. Use of the drug is limited in a significant
proportion of patients as a result of toxicity, with the most
commonly reported side effects being dizziness, nausea and
constipation [22]. Care should be taken with the concomitant
use of serotonin-selective reuptake inhibitors because of
potential elevation of basal serotonin levels, with associated
risks of seizures and/or serotonin syndrome [23].
Non-steroidal anti-inflammatory drugs
The primary anti-inflammatory and antinociceptive effects of
NSAIDs have been linked to an inhibitory effect on cyclo-
oxygenase enzymes and a subsequent decrease in inflam-
matory prostaglandins such as PGE2 and prostacyclin. There
is some evidence for a dissociation between the anti-
inflammatory and antinociceptive effects, in keeping with both
peripheral and central sites of action [24].
NSAIDs have been shown to be highly effective for treating
acute pain (Figure 4) and remain one of the principal
pharmacological agents for treating arthritic pain [25].
Published guidelines and expert opinion are divided over the
relative roles of NSAIDs versus paracetamol as first-line
analgesic therapy for arthritic conditions. A recent meta-
analysis of 15 RCTs involving 5,986 participants concluded
that NSAIDs were superior to paracetamol for improving knee
and hip pain in OA; however, the effect size for both
treatments was modest [26]. NSAIDs are also widely used
for symptomatic therapy for RA, although similarly modest
effects are observed [27].
Concerns about the toxicity of NSAIDs have become more
prominent in recent years. Gastrointestinal events, including
perforation, ulceration and bleeding, are well documented
and a considerable literature is available for review [28].
Other well recognized problems include oedema and renal
insufficiency; however, the development of cyclooxygenase
inhibitors (coxibs) has highlighted additional cardiovascular
risks associated with these agents.
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Figure 4
Oxford league table of commonly used analgesics in acute pain.
Numbers needed to treat for 50% pain relief over 4 to 6 hours are
shown. Note that no comparable data exist for analgesia for chronic
musculoskeletal pain. (Adapted from [50].)International regulatory authorities including the US Food and
Drug Administration and the European Medicines Agency
have issued warnings on the use of coxibs in patients with
increased cardiovascular risk and for long-term use, recom-
mending using the lowest effective dose for the shortest
duration. With evidence that both the traditional non-selective
NSAIDs and coxibs are associated with cardiovascular
adverse events, the broader cardiovascular warning from the
US Food and Drug Administration covers the whole class of
anti-inflammatory analgesics.
Opioids
The long-term use of stronger opioids in chronic musculo-
skeletal conditions remains controversial [29]. Three sub-
classes of opioids receptor have been described – the µ-, δ-
and  κ-opioid receptors – with a widespread distribution
throughout both the central and peripheral nervous systems.
Agonists for the µ-receptor display the best analgesic activity
but also the highest abuse potential.
There is a relative paucity of evidence to support the isolated
use of weaker opioids such as codeine for chronic arthritic
pain [30], but these agents are devoid of serious organ-
damaging effects and when combined with paracetamol may
well be clinically safe for long-term therapy [31].
In those arthritic patients for whom NSAIDs are contra-
indicated or for whom combined therapy is ineffective, the
use of stronger opioids may have a limited role [32]. A
systematic review of 15 RCTs involving 1,025 patients with
chronic non-malignant pain found a mean decrease in pain
intensity in most studies of at least 30%, with a comparable
effect size in both neuropathic and musculoskeletal pain [29].
Recent developments in oral and transdermal sustained-
release formulations have increased the safety and utility of
strong opioid therapy. Transdermal fentanyl has been shown
to be effective in reducing pain scores and improving function
in patients with knee and hip OA [33].
In practice, toxicity issues remain a problem; the most
commonly reported opioid side effects are constipation,
nausea and somnolence [29]. Concerns over abuse potential
remain, although patient education and informed consent,
exercise, complementary medicine and the use of a
controlled-substance agreement increase the likelihood of
patient compliance with treatment guidelines, as well as
improving functional capacity and quality of life [34].
Antidepressants
The antinociceptive action of antidepressants is independent
of their effect on depression and occurs at lower doses and
after a shorter duration of treatment [35]. Tricyclic anti-
depressants have the best antinociceptive efficacy and act to
inhibit uptake of noradrenaline and serotonin, although other
actions have been reported.
The main antinociceptive indication for tricyclic anti-
depressants is for neuropathic pain, although they have
beneficial effects in patients with fibromyalgia as well as back
pain. More modest effects have been noted in RA [36]. For
the most part, these agents remain useful as adjuvant therapy
and are not considered front-line analgesic agents in most
musculoskeletal disorders.
Anti-cytokine therapies
Cytokines released from immune cells as part of the
inflammatory cascade, including IL-1, IL-8 and TNF-α, are
hyperalgesic agents as a result of their ability to stimulate the
production and release of other pro-inflammatory agents such
as bradykinin. Direct effects on primary nociceptors during
inflammatory states may also be clinically relevant. Agents
that suppress the production or actions of TNF-α have been
shown to have potent analgesic activities in clinical trials in
patients with various rheumatic diseases, although whether
there is a dissociation between the anti-inflammatory and
analgesic effects remains to be seen.
Combination analgesics
The relative failure of single pharmacological therapy to
relieve chronic musculoskeletal pain has encouraged the use
of combination therapy [37]. Combinations of paracetamol
plus codeine are widely used although objective evidence for
efficacy is limited by the paucity of clinical trials. Adverse
events limit widespread applicability, although titration of the
dose against effect is useful in overcoming these problems
[38]. More robust evidence supports the use of combinations
of paracetamol plus tramadol [37]. Other clinically useful
strategies include NSAID plus tramadol or NSAID plus weak
opioid, although there are far fewer adequately designed
RCTs to provide objective support for these approaches.
Additional approaches
Topical therapy
Topical NSAIDs have a proven efficacy across a range of
musculoskeletal disorders with fewer side effects than oral
therapy [4]. Although used primarily for neuropathic conditions,
systemic reviews also support the use of topically applied
capsaicin. A limited number of trials report benefit in OA, with
around one-third of patients reporting local adverse events,
usually burning discomfort at the site of application [39].
Intra-articular injections and other local therapies
Intra-articular steroid injections are widely used to control
symptoms in both OA and inflammatory conditions. The
duration of symptom relief may be relatively short in OA, with
effects lasting only a few weeks [40], although longer
responses may occur in RA. Concerns over effects on
cartilage have been partly allayed by studies suggesting no
long-term deleterious events from such therapy [41].
Intra-articular hyaluronic acid (hyluronan) is a high-molecular-
mass polysaccharide with a multiplicity of biological actions
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Symptomatic benefits may be similar to intra-articular
steroids, although the onset of action is delayed, with effects
lasting up to 12 months [42]. Glucosamine and chrondroitin
sulphate have enjoyed striking popularity for the treatment of
OA; they received favourable early reports, but a more recent
large-scale trial failed to show benefit over placebo [43].
Acupuncture
A large proportion of patients with arthritic pain seek help
from complementary or alternative sources, with acupuncture
being a popular choice. Recent individual RCTs have
reported conflicting results [44] in patients with arthritic pain,
although a couple of systematic reviews provided generally
favourable support with symptomatic benefits over both sham
acupuncture and placebo [45]. Overall, acupuncture has a
good safety record with few reports of serious adverse
effects, and it retains a place in the symptomatic manage-
ment of patients with arthritis.
Transcutaneous electrical nerve stimulation
TENS has an established general role in the treatment of
chronic pain, although there have been few studies assessing
the efficacy of the technique for arthritic pain. Underlying
mechanisms of action remain unclear, but in studies of
experimental joint inflammation TENS reduces spinal
stimulatory neurotransmitters (glutamate and aspartate) and
at the same time activates modulatory opioid, serotonin
and/or muscarinic receptors to reduce pain behaviours [46].
In clinical studies, TENS has been found to be as effective as
exercise and better than placebo for controlling arthritic pain,
although combination approaches produce the most
favourable result [47].
Conclusion
The mechanisms of chronic pain differ from those of acute
pain. Although peripheral tissue injury is undoubtedly
important for the initiation and maintenance of arthritic pain,
more central factors, involving changes to pain pathways,
become equally important with time. Strategies for treating
arthritic pain need to embrace this reality and will necessarily
involve multimodal therapy with both pharmacological and
non-pharmacological measures (Figure 5). Despite the
theoretical advantages, there is a paucity of objective clinical
evidence to show the benefits of using an integrated
approach for analgesia in persistent joint pain. Designing and
evaluating complex interventions to improve health care pose
a considerable challenge and require a substantial investment
of time and financial resource [48] but nevertheless remain a
key priority for clinical research into musculoskeletal disease.
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